The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea (Q34432129)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea (English)

1 reference

Europe PubMed Central

2 August 2017

Helicobacter pylori

0 references

6

object named as

Nayoung Kim

1 reference

Europe PubMed Central

2 August 2017

Sook-Hyang Jeong

7

object named as

Sook Hyang Jeong

1 reference

Europe PubMed Central

2 August 2017

author name string

Kwang Hyun Chung

1

1 reference

Europe PubMed Central

2 August 2017

Dong Ho Lee

2

1 reference

Europe PubMed Central

2 August 2017

Eunhyo Jin

3

1 reference

Europe PubMed Central

2 August 2017

Yuri Cho

4

1 reference

Europe PubMed Central

2 August 2017

Ji Yeon Seo

5

1 reference

Europe PubMed Central

2 August 2017

Jin Wook Kim

8

1 reference

Europe PubMed Central

2 August 2017

Jin-Hyeok Hwang

9

1 reference

Europe PubMed Central

2 August 2017

Cheol Min Shin

10

1 reference

Europe PubMed Central

2 August 2017

publication date

15 November 2014

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

8

1 reference

Europe PubMed Central

2 August 2017

6

1 reference

Europe PubMed Central

2 August 2017

605-611

1 reference

Europe PubMed Central

2 August 2017

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Epidemiology of Helicobacter pylori infection and public health implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Moxifloxacin: a review of its use in the management of bacterial infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Recent developments in the epidemiology of Helicobacter pylori

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

6 July 2018

Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215445

27 October 2018

Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population

1 reference

https://pubmed.ncbi.nlm.nih.gov/25368747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report

1 reference

https://pubmed.ncbi.nlm.nih.gov/25368747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/25368747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Helicobacter pylori density on inflammatory activity in stomach

1 reference

https://pubmed.ncbi.nlm.nih.gov/25368747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.5009/GNL13303

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34432129&oldid=1945764462"